866-997-4948(US-Canada Toll Free)

Ventavis (iloprost) - Analysis and Estimates from 2003 to 2017

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 37 Pages



GlobalDatas pharmaceuticals report, Ventavis (iloprost) Analysis and Estimates from 2003 to 2017 provides Ventavis sales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2003-2017). The report also includes information on Pulmonary Arterial Hypertension market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Ventavis including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Ventavis including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2003-2017 for Ventavis in the US and EU5
Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Pulmonary Arterial Hypertension 4
2.2 Epidemiology 4
2.2.1 Prevalence 4
2.2.2 Mortality 5
2.3 Etiology 5
2.3.1 Scleroderma 5
2.3.2 Sickle Cell Disease 5
2.3.3 HIV/AIDS 5
2.3.4 Drug Abuse and Toxins 5
2.4 Economic Impact of PAH 5
2.5 GlobalData Report Guidance 6

3 Pulmonary Arterial Hypertension (PAH): Market Characterization 7
3.1 PAH Market 7
3.2 PAH Market Forecasts and CAGR 8
3.3 PAH Market : Drivers and Restraints 8
3.3.1 Drivers 9
3.3.2 Barriers 10

4 Classification of PAH 11
4.1 Classification Based on Cause and Clinical Presentation 11
4.1.1 Idiopathic PAH 11
4.1.2 Familial PAH 11
4.1.3 Drug Induced PAH 11
4.1.4 PAH Associated with Other Conditions 11
4.1.5 PAH Associated with Significant Venous or Capillary Involvement 11
4.2 Symptomatic Profile of PAH 11

5 Evolution of PAH Treatments 12

6 Medications 13
6.1 Prostanoids 13
6.1.1 Epoprostenol 13
6.1.2 Treprostinil 13
6.1.3 Iloprost 13
6.1.4 Beraprost 13
6.2 Endothelin Receptor Antagonists 13
6.2.1 Bosentan 13
6.2.2 Ambrisentan 14
6.2.3 Sitaxsentan 14
6.3 Phosphodiesterase Type 5 Inhibitors 14
6.3.1 Sildenafil 14
6.3.2 Tadalafil 14
6.4 Surgical Treatments 14
6.5 Investigational Combination Regimens 15
6.6 New Targets for PAH Therapy 15

7 Market Share by Class in PAH 17

8 Ventavis (iloprost) 18
8.1 Introduction 18
8.2 Mechanism of Action 18
8.3 Clinical Studies 18
8.4 Approval History of Ventavis 20
8.5 Factors Affecting Sales of Ventavis 20
8.5.1 Approval for Increased Strength Formulation 20
8.5.2 Less Preferred Choice of Treatment 20
8.5.3 Competition from Tyvaso 21
8.5.4 Expiry of Orphan Drug Status 21
8.6 Drug Evaluation 21
8.6.1 Drug Risk Benefit Score 21
8.6.2 Intensity of Competition 22
8.7 Sales Estimates 22
8.7.1 Target Patient Pool of Ventavis 22
8.7.2 Dosing 23
8.7.3 Market Penetration 23
8.7.4 Annual Cost of Therapy 23
8.7.5 Sales Projections of Ventavis 24

9 PAH Market: Appendix 32
9.1 Market Definitions 32
9.2 List of Abberiviations 32
9.3 Research Methodology 33
9.3.1 Coverage 33
9.3.2 Secondary Research 33
9.3.3 Forecasting 33
9.3.4 Number of Patients Approved to take the Drug 34
9.3.5 Net Penetration of Drug 34
9.3.6 Net Annual Dosing 35
9.3.7 Annual Cost of Therapy 35
9.3.8 Primary Research 35
9.3.9 Expert Panels 35
9.4 Drug Sales Estimates Model 36
9.5 Contact Us 36
9.6 Disclaimer 36
9.7 Sources 36

List of Table


Table 1: PAH, Global, Major Marketed Drugs 7
Table 2: PAH, Global, Pipeline (Phase III) 8
Table 3: PAH Drugs Evolution 12
Table 4: Change from Baseline to Week-12: Hemodynamic Parameters 19
Table 5: Treatment Effects of Ventavis among PAH Patients 19
Table 6: Adverse Events in Phase III Clinical Trials of Ventavis 20
Table 7: Approval History of Ventavis 20
Table 8: Drug Risk Benefit Score of Ventavis 21
Table 9: Ventavis, Annual Cost of Therapy in PAH, Global, 2010 23
Table 10: Ventavis, PAH, Global, Sales Estimates ($m), 20032017 24
Table 11: Ventavis, PAH, The US, Sales Estimates ($m), 20052017 25
Table 12: Ventavis, PAH, The UK, Sales Estimates ($m), 20032017 26
Table 13: Ventavis, PAH, France, Sales Estimates ($m), 20032017 27
Table 14: Ventavis, PAH, Germany, Sales Estimates ($m), 20032017 28
Table 15: Ventavis, PAH, Italy, Sales Estimates ($m), 20032017 29
Table 16: Ventavis, PAH, Spain, Sales Estimates ($m), 20032017 30

List of Chart


Figure 1: PAH, Global, Market Size Forecasts ($bn), 20102020 8
Figure 2: PAH, Worldwide, Market Share by Class (%), 2010 17
Figure 3: Drug Model Diagram of Ventavis 22
Figure 4: Ventavis, PAH, Global, Sales Estimates ($m), 20032017 24
Figure 5: Ventavis, PAH, The US, Sales Estimates ($m), 20052017 25
Figure 6: Ventavis, PAH, The UK, Sales Estimates ($m), 20032017 26
Figure 7: Ventavis, PAH, France, Sales Estimates ($m), 20032017 27
Figure 8: Ventavis, PAH, Germany, Sales Estimates ($m), 20032017 28
Figure 9: Ventavis, PAH, Italy, Sales Estimates ($m), 20032017 29
Figure 10: Ventavis, PAH, Spain, Sales Estimates ($m), 20032017 30
Figure 11: Ventavis, PAH, Global, Sales Distribution by Country (%), 2011 31
Figure 12: Drug Model Diagram 34
Figure 13: Patients Approved for the Drug 35

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *